市场在为什么买单
What the Market Is Paying For

Most astaxanthin research on exercise metabolism has historically focused on male subjects, leaving a gap in our understanding of how the ingredient affects women, even though women are a major consumer segment for this antioxidant carotenoid. A new study helps address that gap, and its results suggest that astaxanthin's effects on fuel metabolism during exercise may be relevant for women.

Study Design

Twenty recreationally active young women took astaxanthin for two weeks, then completed a 30-minute continuous cycling test in which intensity rose progressively from 40% to 65% of maximum power output. Researchers measured the respiratory exchange ratio (RER), an indicator of whether the body is burning proportionally more fat or more carbohydrate, alongside heart rate, blood lactate and perceived exertion.

Key Findings

RER was significantly lower after astaxanthin supplementation than after placebo across the cycling session, consistent with a shift toward greater reliance on fat as fuel at these submaximal intensities. The shift occurred without corresponding changes in heart rate, blood lactate or perceived exertion. Participants were not working harder, and did not feel they were, even though their muscles were sourcing energy differently.

According to AstaReal's vice president, this decoupling of perceived effort from fuel use is one of the more interesting findings. It suggests that astaxanthin's effect may operate at the level of metabolic substrate rather than through a general performance or effort-tolerance mechanism.

Why the Focus on Women Matters

The researchers noted that women typically rely more on fat oxidation during exercise than men do at baseline, raising the possibility that they could respond differently, and potentially more favorably, to an ingredient that further nudges fuel use toward fat. Because most prior astaxanthin-and-exercise research has been conducted in male cohorts, this study provides some of the first sex-specific clinical evidence in the area.

Relevance for Product Positioning

For companies formulating astaxanthin-based sports nutrition or metabolic-health products, the study offers a mechanistically grounded rationale — fat utilization at submaximal intensities without added perceived effort — that may inform messaging for active women, a segment comparatively underserved in astaxanthin's clinical evidence base. Any resulting claims should go through regulatory review.

Most astaxanthin research on exercise fatigue has focused on the purified compound in isolation. A new study from South Korean researchers takes a different approach: it tests the whole-algae extract itself and examines the biological pathways behind its anti-fatigue effects.

Study Design

Researchers evaluated a Haematococcus pluvialis extract, designated YHC-T-2414, in muscle cell cultures and in mice. They examined whether it could reduce oxidative stress, support mitochondrial function, increase exercise performance and reduce fatigue through identifiable pathways, rather than through astaxanthin content alone.

Why Fatigue Happens, and Where This Extract May Act

Exercise-induced fatigue is characterized by physical and mental exhaustion from prolonged exertion and accumulated stress. One well-established contributor is oxidative stress: when reactive oxygen species (ROS) build up faster than the body can clear them, they damage muscle tissue and mitochondria and impair the muscle's ability to produce energy efficiently. In this study, YHC-T-2414 was associated with activation of AMPK, a cellular energy-sensing pathway, together with enhanced antioxidant defenses and support for mitochondrial biogenesis, the process by which cells generate new, functional mitochondria.

Whole Extract vs. Purified Compound

The researchers framed their contribution as mechanistic evidence for the anti-fatigue activity of the whole H. pluvialis extract, rather than attributing effects to purified astaxanthin alone. The distinction matters because whole-algae extracts contain a range of co-occurring compounds that could plausibly contribute to, or interact with, the observed effects. Some study authors were affiliated with Yuhan Care Co., the supplier of the extract used, which is relevant when weighing the strength of the evidence.

Limitations and Next Steps

The researchers were direct that further studies are needed to confirm whether the signaling pathways seen in cells and mice are similarly activated in human skeletal muscle after YHC-T-2414 administration. This remains preclinical, mechanistic evidence, not confirmed human clinical benefit.

Relevance for Ingredient Positioning

For companies working with astaxanthin-rich algae extracts, the research suggests a mechanism-first positioning angle — AMPK activation, antioxidant defense and mitochondrial biogenesis — that goes beyond generic antioxidant messaging and supports a 'whole extract' distinction from purified astaxanthin ingredients. Human clinical confirmation would meaningfully strengthen any claims basis.

A recent article in The Oasis Health Journal takes a skeptical look at claims that fucoxanthin supports mitochondrial function in humans. Its main point is that much of the mechanistic evidence remains preclinical.

What the Evidence Covers

Reviews cited by the article describe effects of fucoxanthin on pathways such as AMPK, mTOR, autophagy, redox balance and metabolic resilience. However, the supporting studies are largely cell or animal studies, primarily in rodents, rather than human trials with direct mitochondrial outcomes. The article did not identify an established human dose or a validated mitochondrial outcome measure.

The Bioavailability Gap

A central issue is oral bioavailability. In the gastrointestinal tract, fucoxanthin is converted to fucoxanthinol, and systemic exposure is limited. The article argues that this creates an important gap between the concentrations used in controlled laboratory experiments and the exposure realistically reached through supplementation.

Product Labeling

The article also notes that commercial products may list brown-seaweed extract amounts without clearly stating actual fucoxanthin content, which makes products hard to compare. It concludes that improved delivery systems, metabolite tracking and adequately powered human trials are needed before strong mitochondrial-health claims can be supported.

Relevance to BGG

According to the contributor, the article is highly relevant to BGG's fucoxanthin program. It points to areas where a premium product could differentiate: clearly standardized fucoxanthin content, a formulation designed for absorption, direct pharmacokinetic measurement of fucoxanthinol, and carefully designed human clinical trials. It is also a reminder to keep marketing claims aligned with the actual level of human evidence.

Sarcopenia, the progressive loss of muscle mass and strength with aging, is increasingly understood to involve the gut-muscle axis. A new large-scale study combining several population datasets with laboratory and computational modeling adds to the case that probiotics may play a protective role.

Study Design

Researchers combined data from three sources — the US NHANES survey, UK Biobank and the GMrepo gut microbiome database — with muscle-cell experiments, molecular docking analysis and machine-learning models. The aim was to examine how probiotic use and probiotic-associated gut bacteria relate to sarcopenia risk, looking at real-world population associations alongside more mechanistic, cell-level evidence.

Findings

In all three population datasets, diagnosed sarcopenia was less common among probiotic users than non-users: 20% versus 26% in NHANES, 20% versus 24% in UK Biobank, and 18% versus 26% in the microbiome-based GMrepo analysis. The consistency of the pattern across three independent, methodologically different datasets strengthens the signal compared with any single study, although these are associations and do not establish cause and effect.

Proposed Mechanisms

The researchers point to several processes known to drive age-related muscle loss: chronic low-grade inflammation, mitochondrial dysfunction, reduced muscle protein synthesis, anabolic resistance and broader metabolic dysfunction. They propose that probiotics may counteract these processes through the gut-muscle axis, the two-way communication pathway through which gut bacteria influence systemic inflammation, nutrient absorption, metabolism and, ultimately, muscle function. Based on their combined population, laboratory and computational findings, they concluded that probiotic supplementation may offer a clinically relevant benefit to older adults' skeletal muscle health through combined anti-inflammatory, mitochondrial-support and anabolic-regulatory effects rather than a single mechanism.

An Emerging Application Area

The work adds probiotics to a growing list of gut-microbiome-linked interventions explored for sarcopenia prevention, alongside approaches such as targeted amino acid and omega-3 supplementation. The researchers also raise a longer-term vision: using microbial profiles and AI-based risk prediction to enable more personalized, precision-nutrition approaches to sarcopenia prevention.

Relevance for Healthy-Aging Product Strategy

For companies developing healthy-aging or muscle-health products, the cross-dataset evidence supports considering probiotics as a complementary strategy alongside more established measures such as resistance exercise and protein supplementation. This may be particularly relevant for frail or less mobile older adults, for whom exercise alone can be hard to implement.

Probiotics have increasingly moved beyond digestive health into sports nutrition. A new Taiwanese study adds clinical evidence for one specific strain, Lactiplantibacillus plantarum GKK1, after a relatively short four-week supplementation period.

Study Design

Forty-eight healthy, sedentary adult men were randomly assigned to placebo or L. plantarum GKK1 for four weeks. At the end of supplementation they completed a standardized, high-intensity plyometric protocol of 100 maximal vertical jumps, an established way to induce exercise-related muscle damage in a laboratory.

Findings

GKK1 supplementation significantly reduced the severe post-exercise depletion of serum dopamine seen in the placebo group, and attenuated acute adrenaline spikes tied to the exercise stress response. Based on these biomarker changes, the researchers suggested that GKK1 may reduce post-exercise fatigue and muscle damage through a combination of anti-inflammatory, muscle-protective, metabolic and neuroendocrine effects, rather than a single mechanism.

Consistent With a Broader Body of L. plantarum Research

The finding adds to a growing, strain-specific body of evidence on L. plantarum in sports contexts. Other strains of the species, including PS128 and PL-02, have separately shown benefits such as faster recovery of exercise capacity after endurance events like half-marathons, and reductions in muscle damage, oxidative stress and systemic inflammation in athletes. Because efficacy in this category tends to be strain-specific rather than a species-level effect, GKK1's results should be read as evidence for this strain, not for L. plantarum broadly.

Limitations Noted by the Researchers

The authors noted several limitations: a narrow population (healthy, sedentary men), a short four-week intervention, and no gut microbiome analysis, which would have helped clarify whether the effects are mediated by microbiome changes or by more direct systemic pathways.

Relevance for Sports Nutrition Formulation

For companies developing recovery-focused sports nutrition products, the study adds a strain-specific data point to the case for probiotics as a recovery aid, distinct from and potentially complementary to established ingredients such as protein, tart cherry or omega-3s. As with other strain-specific research, strain identity (GKK1 here) should be central to any resulting claims.

A randomized, double-blind, placebo-controlled 90-day clinical trial has examined fucoidan derived from Undaria pinnatifida in men with moderate benign prostatic hyperplasia (BPH), as reported by Nutritional Outlook.

Trial Design

Ninety-five men aged 45 to 80 were randomized to 1 g/day of fucoidan or placebo for 90 days; 88 completed the study per protocol.

Results

On the primary endpoint, the International Prostate Symptom Score (IPSS), the fucoidan group improved significantly more than placebo by days 60 and 90. The mean IPSS change at day 90 was -3.40 with fucoidan versus -0.93 with placebo. Responder analyses also favored fucoidan: 51.1% of men achieved an IPSS reduction of at least 3 points, compared with 28.9% on placebo (p=0.0314).

Objective secondary measures showed more limited separation between groups. Peak urinary flow (Qmax) rose by 1.13 mL/s with fucoidan and 0.09 mL/s with placebo, a between-group difference that was not statistically significant. Post-void residual volume also showed limited separation, and PSA did not change meaningfully. The ingredient was generally well tolerated.

Limitations

The article notes a modest sample size, a relatively short study duration and sponsor involvement; the trial was funded by Marinova Pty Ltd.

Relevance to BGG

According to the contributor, the trial is a useful benchmark for clinical development of marine polysaccharides. It shows that fucoidan may be positioned beyond broad immune or gut-health messaging toward a more targeted men's-health application when supported by randomized human data. For BGG, it may be worth considering both for fucoidan opportunity assessment and for designing evidence packages around marine-derived ingredients.

Hair-growth supplements are usually evaluated on measures such as hair density or total hair count. A new company-funded study from Nutrafol's parent company, Nutraceutical Wellness, instead focuses on a less commonly reported measure: linear hair growth rate (LHGR), which describes how quickly individual hairs grow over a given period rather than how many hairs are present.

Why Growth Rate Is a Different Metric

According to Dr. Isabelle Raymond, senior vice president of global clinical and medical affairs at Nutrafol, growth rate offers manufacturers and clinicians information that density alone cannot capture. A product could show improved hair density over time without accelerating how fast existing hairs grow, and a genuine improvement in growth rate might not show up clearly in density measurements over shorter studies. Tracking LHGR addresses that gap.

Study Findings

Across four Nutrafol formulations, the study reported average hair growth rate increases of 18.6% to 36.7% relative to participants' baseline. Secondary measures also improved, including a greater proportion of hairs in the active growth stage, higher terminal hair counts and improved overall scalp coverage.

Funding and Independence

As with much of the published research on Nutrafol, the study was funded by Nutraceutical Wellness, which also covered the publication fees. Two authors are current company employees, one previously worked for the company, and another, who served as scientific adviser, received research funding from Nutraceutical Wellness. This structure is a standard consideration for company-sponsored research and does not necessarily undermine the findings, but it is relevant to how much claim support the data can provide.

Relevance for Category Benchmarking

For companies developing or evaluating hair-health ingredients, LHGR may be worth considering as an additional or alternative primary endpoint alongside density and count measures, particularly for studies aiming to detect functional changes over shorter timeframes. As the category moves beyond legacy ingredients such as biotin and collagen toward more mechanistically diverse formulations, endpoint selection is becoming a point of scientific and marketing differentiation.

Nutritional Outlook reports on a 28-day, dermatologically supervised evaluation of TriNutra's standardized black seed oil ingredient, B'utyQuin, formulated at 5% in a scalp lotion. The study combined instrumental hair-density measurements, a standardized dry-hair-loss test and dermatologist-supervised tolerability assessments.

What Was Reported

Twenty-two adults took part. Participants reported favorable outcomes: 82% reported reduced shedding, 82% reported visible stimulation of new growth, 77% reported stronger or more voluminous hair, and 95% rated the lotion gentle.

Important Limitation

The study had no placebo or vehicle-control arm, so the observed effects cannot be attributed to the active ingredient with the same confidence as in a randomized controlled trial. Several of the reported outcomes are participants' own assessments.

Positioning and Proposed Mechanisms

The ingredient is positioned for scalp health and cosmetic hair-appearance support, not as a treatment for alopecia. Proposed mechanisms include effects on mitochondrial function, ATP production, antimicrobial activity and the scalp microbiome.

Relevance to BGG

According to the contributor, the main relevance is methodological and commercial. The study illustrates how a natural active can generate cosmetic claim-support data relatively quickly using instrumental endpoints. For BGG's cosmetic ingredients, similar short, well-controlled studies could offer a faster route to differentiated claims, and adding a vehicle control would materially strengthen the evidence.

As dietary supplement use rises globally, a new survey of healthcare practitioners points to a persistent gap: most clinicians recognize that herb-drug interactions (HDIs) matter, but relatively few have detailed, specific knowledge of them, and fewer still routinely ask patients about supplement use.

Study Design

Researchers from the University of Coimbra in Portugal ran an online survey of 311 healthcare practitioners to assess their awareness and knowledge of HDIs. The survey covered general attitudes toward the clinical relevance of these interactions as well as applied knowledge of specific interaction risks.

Key Findings

While 90.6% of respondents recognized that HDIs are clinically relevant in principle, knowledge of specific interactions was limited. Only 57.6% of practitioners reported routinely asking patients about their use of food supplements or herbal products, which suggests that a meaningful share of patient supplement use may go undiscussed in clinical settings.

The researchers also flagged limited clinician awareness of how supplement quality defects, such as contamination with microorganisms, mycotoxins or pesticide residues, or the presence of undisclosed toxic elements, can change a patient's actual exposure. This complicates attributing an adverse clinical event to either the supplement or a co-administered medication.

A Persistent Disclosure Gap

The study cites 2022 survey data from Food Supplements Europe indicating that roughly 88% of EU respondents had used a supplement at least once in their lifetime. Non-disclosure of supplement use to healthcare professionals is estimated at 40% to 70%, commonly because patients are never asked, assume the products are inherently safe, or do not consider them relevant enough to mention.

Relevance for Quality and Regulatory Strategy

For supplement manufacturers, the research reinforces two points. First, quality control and contamination-risk mitigation remain important, since clinicians may be poorly placed to catch or interpret adverse effects from a contaminated product. Second, there is an opportunity for the industry, through packaging, patient education materials or professional outreach, to help close the disclosure gap between patients and healthcare providers, given its bearing on patient safety and the credibility of the supplement category.

2026年6月，一项发表于《Frontiers in Nutrition》的随机、双盲、安慰剂对照临床研究提示，标准化藏红花提取物（Affron®）与50–70岁女性情绪状态及睡眠相关日间功能的改善相关，但睡眠障碍本身未见显著变化。

研究设计与结果

该研究由Adrian L. Lopresti团队完成，共纳入86名同时存在低情绪和睡眠问题的女性受试者，每日补充28 mg标准化藏红花提取物，持续12周。结果显示，藏红花组的DASS-21抑郁评分下降幅度优于安慰剂组（组间差异2.37分，Cohen's d为0.48），48.8%的参与者达到具有临床意义的改善，安慰剂组为25.6%。

在睡眠维度，藏红花组“睡眠相关功能受损”指标改善更明显（组间差异2.99分，Cohen's d为0.45），即睡眠问题对日间功能的负面影响有所减轻，但“睡眠障碍”本身未见显著变化。此外，藏红花组的Rosenberg自尊评分也有所改善（组间差异1.43分，Cohen's d为0.51）。

研究者指出，该研究最明确的信号来自情绪改善，而非直接助眠。更准确的理解是，藏红花在“情绪—睡眠—日间状态”这一交叉健康场景中显示出研究潜力。

此前的相关研究

此前多项研究已探讨藏红花与睡眠的关系。2020年，Lopresti等人在63名睡眠不佳的成年人中报告，每日两次、每次14 mg藏红花提取物与失眠严重程度和恢复性睡眠的改善相关；2021年一项研究在66名轻至中度睡眠障碍伴焦虑的人群中，观察到卧床时间增加、入睡困难改善等变化；同年，Lopresti团队在120名睡眠不佳者中开展多剂量研究，发现14 mg和28 mg两个剂量均与睡眠质量、醒来后情绪及失眠指标的改善相关，并观察到夜间唾液皮质醇的变化。2025年一项纳入165名中度失眠者的研究报告，20 mg或30 mg藏红花提取物与AIS量表所示失眠症状减轻相关，睡眠质量自第3周起改善，感知压力同时下降。

2026年6月18日，一篇系统综述为压力管理提供了新视角：芦笋（Asparagus officinalis）这种常见蔬菜，正成为功能食品领域的新兴研究对象。该综述汇总了18项临床研究（共503名受试者），系统评估了芦笋茎的摄入对睡眠、压力、情绪和认知的影响。

综述观察到什么

综述显示，芦笋补充剂在健康成年人中观察到的变化主要包括：（1）睡眠质量和睡眠时间的改善最为一致；（2）白天精神疲劳和反应速度有所改善；（3）焦虑、抑郁等压力相关指标呈下降趋势；（4）部分研究还观察到皮质醇等生物标志物的积极变化。

值得注意的是，这些受试者大多并非失眠患者，而是健康成年人，或存在轻度睡眠困扰、工作压力较大的人群。这表明芦笋的定位更倾向于帮助亚健康人群提升恢复质量，而非治疗睡眠障碍。

值得关注的活性成分：芦笋多糖

另有综述指出，未来值得关注的芦笋活性成分可能是芦笋多糖这类天然大分子。研究认为，芦笋多糖除具有抗氧化作用外，还可能通过以下途径发挥作用：（1）调节肠道菌群；（2）增加短链脂肪酸（尤其是丁酸）的产生；（3）改善肠道屏障功能；（4）降低炎症因子释放；（5）通过肠-脑轴（Gut-Brain Axis）影响脑功能和神经炎症。

可能的作用机制

关于其作用机制，现有研究主要围绕4条路径展开：一是激活热休克蛋白70（HSP70），提升细胞对应激的防御能力；二是调节下丘脑-垂体-肾上腺轴（HPA轴），帮助机体维持正常的应激节律；三是改善氧化应激与慢性炎症；四是通过肠-脑轴调节肠道微生态，提高机体对应激的适应能力。研究者认为，芦笋并非直接“消除压力”，而是可能通过增强细胞自身的应激防御能力，帮助机体从压力状态中更好地恢复。

高尿酸血症已成为继高血压、高血糖、高血脂之后的“第四高”。流行病学数据显示，我国成人居民患病率已达14.0%，并且在18～29岁青年男性中攀升至32.3%。尿酸异常升高是痛风、肾结石、心血管疾病及糖尿病的重要相关因素。

近期，一项研究被《Food & Medicine Homology》接收，探讨了被誉为“香料之王”的黑胡椒在尿酸调节方面的潜力。研究发现，传统药食同源植物黑胡椒的提取物及其主要活性成分，在动物试验中显示出“抑制尿酸生成、促进尿酸排泄、减轻肾脏炎症损伤”三方面相关作用。

动物试验的三点发现

抑制尿酸生成：黑胡椒提取物可通过JAK2/STAT3信号通路抑制黄嘌呤脱氢酶（XDH）的表达，并抑制黄嘌呤氧化酶（XO）活性，与小鼠肝脏尿酸合成减少相关。

促进尿酸排泄：黑胡椒提取物可抑制小鼠肾小管细胞中的尿酸重吸收蛋白GLUT9，与尿酸重吸收减少、经肾脏排出增加相关。

减轻肾脏炎症：黑胡椒提取物可抑制JAK2/STAT3通路，减少炎症因子TNF-α的分泌，与小鼠肾脏炎症和组织损伤的减轻相关。

活性成分与产业背景

现代植物化学研究表明，黑胡椒的主要活性成分为生物碱（以胡椒碱为主）、挥发油、黄酮类等。除上述尿酸相关研究外，这些成分还被认为可能具有抗炎、抗氧化、免疫调节及促进营养物质吸收等作用。有研究报道，胡椒碱可将姜黄素的生物利用度提升2000%，将辅酶Q10的生物利用度提升约30%，将β-胡萝卜素的生物利用度提高60%。

黑胡椒于2002年被原卫生部列入首批《既是食品又是药品的物品名单》。据Business Research Insights数据，到2035年全球黑胡椒市场收入预计将达到51.4亿美元。

需要说明的是，以上机制均来自动物试验，其在人体中的作用尚待临床研究验证。

日本Octroll公司将运用葫芦巴（Fenugreek，学名 Trigonella foenum-graecum）种子提取物“TestSurge”在提升血液NAD⁺水平等方面的新发现，进一步强化其用途提案。

该功能性原料由印度Indus Biotech公司制造，按总糖苷含量80%以上标准化，含有甾体糖苷与黄酮苷。Indus Biotech公司已积累大量证据数据。作为新证据，在112人、为期12周的摄取试验中，试验组与安慰剂组相比，血液NAD⁺水平与血液ATP浓度显著增加，研究成果已论文发表。此外，细胞试验亦确认其对NAD⁺分解酶CD38具有抑制作用。

该原料在北美等海外市场流通业绩丰富，日本本土的产品采用案例也持续增长，已取得“Informed Ingredient”与“BSCG（Banned Substances Control Group）”反兴奋剂认证。目前，Octroll正围绕活力维持、男性更年期相关（原稿表述为“男性更年期改善”）以及运动营养领域推进应用提案。

日本Omnica公司已启动下一代益生元素材“Rinside（酵母细胞壁粉末）”的样品发放工作。该粉末产品的主要成分为β-葡聚糖与甘露聚糖，分别标准化至20%以上。相对于需要以克为单位摄取的益生元素材，据称“Rinside”每日500 mg即有望发挥作用。

该公司还介绍，“Rinside”不易在肠道早期阶段被分解，并与肠道菌群中拟杆菌门（Bacteroidetes）的增殖相关，公司将此点视为其显著特点。

功能性研究提示，其作用可能因肠道菌群类型而异：大量摄取蔬菜、水果者的“普雷沃氏菌型（Prevotella）”，摄取食物种类广泛者的“拟杆菌型（Bacteroides）”，以及大量摄取肉类者。该公司提议将其开发为合生元产品或应用于青汁，目标为产短链脂肪酸的菌群，且不局限于特定肠型。除成本优势外，该公司亦重点推介其混入青汁或饮料时几乎不影响流动性与黏度的特性。

——Omnica公司

日本Oriental酵母工业（Oriental Yeast Co., Ltd.）已开始面向男性市场推出功能性原料“洋葱氨基酸P（Onion Amino Acid P）”，并计划于10月日本“食品开发展2026”出展推介。

该原料含异蒜氨酸（Isoalliin）、甲蒜氨酸（Methiin）、环蒜氨酸（Cycloalliin）等含硫氨基酸（sulfur-containing amino acid），公司称其抗氧化能力优异，含硫氨基酸含量约为生洋葱的47倍。原料来源为具有长期食用历史的洋葱，公司称其功效也有相应的科学证据支持。

人体试验与功能标示

在一项针对50～79岁男性（48人，AMS评分27～49分）的人体临床试验中，受试者摄取后唾液中睾酮水平高于摄取前，身体因子、心理因子、性机能因子的评分也有改善。

基于上述研究，该产品以“据报告，有助于维持自觉有随加龄易感之身体状态变化（排除病理性、慢性情形）的健康中老年男性的心理状态（随加龄易下降的平静心情、愉悦安稳心情）”的功能标示，在日本获得功能性标示食品受理。

注：AMS评分（Aging Males' Symptoms Score）为男性更年期障碍问卷。

近年来，国际快消与健康巨头密集并购“科学营养 / 高端膳食补充剂”标的：从雀巢 57.5 亿美元入场、宝洁 38 亿美元收购 Thorne，到麒麟连续拿下澳佳宝、芳珂、健美生，赛道正从“大众保健品”向“有临床背书的科学营养资产”升级。本报告梳理 2020 年至今 24 起代表性交易（含 1 起反向出售），数据截至 2026 年 9 月 11 日。

核心速览

· 案例数量：24 起代表性交易（含 1 起反向出售），覆盖 2020 年至今。

· 活跃买家（8 家）：雀巢、联合利华、麒麟、达能、宝洁、百事、拜耳、费列罗。

· 累计金额：据报告统计，已披露案例累计金额约 220 亿美元（美元近似，不含未披露项）。

· 2026 年：宝洁、麒麟、达能、联合利华、雀巢年内集中落子，为并购集中出现的一年。

· 后续处置：雀巢已就 2021 年收购的 Bountiful 核心品牌及 Nuun 中的大众品牌达成出售协议，拜耳 2020 年收购的 Care/of 已停止运营，GO Healthy 正在战略审查——并购后同样存在快速处置、止损离场的情况。

一句话结论

代表性交易一览

注：金额为公开披露或权威媒体报道口径；“约”表示媒体或换算近似值；未正式披露的金额以媒体估算标注。

按买家看：雀巢的“买—卖”双向操作

2020 年 6 月，雀巢取得 Vital Proteins 多数股权，切入胶原蛋白/美容营养赛道，2022 年 2 月完成全资收购。2021 年 4 月，雀巢以 57.5 亿美元从 KKR 手中收购 The Bountiful Company 核心品牌（自然之宝、Solgar、关捷健、普丽普莱等），同年 8 月完成交割，是雀巢历史上在营养保健领域的最大手笔之一。2022 年 9 月，雀巢完成收购新西兰 The Better Health Company（含 GO Healthy 品牌），企业价值约 3.75 亿新西兰元；2026 年 8 月，雀巢宣布对该业务启动战略审查，评估包括出售在内的各种选项。2026 年 6 月，雀巢宣布收购德国 yfood Labs 剩余 51% 股权（此前已持 49%），7 月初完成全资控股，整体估值约 4.5 亿欧元。

反向案例出现在 2026 年 9 月 1 日：雀巢宣布以 10 亿美元将“Holistic Health”大众 VMS 组合出售给美国私募 Yellow Wood Partners，涵盖自然之宝、关捷健、Ester-C、Gard、Nuun、普丽普莱、Sisu 七个品牌及美国自有品牌膳食补充剂业务与配套设施，该业务 2025 年销售额约 12 亿美元，预计 2027 年上半年交割。雀巢明确保留 Solgar、Pure Encapsulations 等 premium, science-led VMS 品牌。

联合利华：从补水、软糖到临床护发

联合利华在 2020—2022 年连续布局：2020 年 10 月完成收购电解质补水品牌 Liquid I.V.，收购以来业务规模增长约四倍，已成为其健康业务营收最大的品牌；2020 年 11 月收购高端复合维生素软糖 SmartyPants Vitamins；2021 年 4 月收购功能营养品牌 Onnit（金额未披露，媒体估测约 1—4 亿美元）；2022 年 5 月以约 8.11 亿欧元收购以临床研究为基础的口服护发营养品牌 Nutrafol 的 67% 股权，并于 2025 年完成对剩余股权的收购。2026 年，印度联合利华（HUL）于 2 月以 82.4 亿卢比（约 9,090 万美元）收购 OZiva 剩余 49% 股权；联合利华 4 月宣布收购美国 Grüns，6 月完成交割，公司未正式披露金额，媒体估值约 12 亿美元。

麒麟：三年三笔，铺开全球健康科学版图

2023 年 8 月，麒麟以 18.8 亿澳元完成收购澳大利亚 Blackmores（澳佳宝）；2024 年 6 月启动对日本 FANCL（芳珂）的要约收购，总价约 2,100 亿日元，同年 12 月 FANCL 退市；2026 年 8 月 7 日，麒麟宣布以每股 45.75 加元现金收购加拿大 Jamieson Wellness（健美生）全部普通股，股权价值 18.98 亿加元，企业价值约 25 亿加元，预计 2026 年第四季度完成交割。三笔交易使麒麟形成横跨日本、澳新与北美的布局。

达能、宝洁及其他买家

达能：2025 年 6 月收购比利时肠道微生物组公司 The Akkermansia Company（金额未正式披露，业内估算 1.5—2.5 亿美元）；2026 年 3 月宣布收购英国 Huel，媒体口径约 10 亿欧元；2026 年 6 月宣布从 TPG 手中全资收购澳大利亚 MADE Group（金额未披露，其 FY2026 销售额超 3 亿欧元）。

宝洁：2026 年 8 月 4 日宣布以 38 亿美元现金从 L Catterton 手中收购 Thorne，预计 2026 年第四季度完成交割；报告称宝洁此前击败了联合利华、赫力昂等竞购对手。Thorne 在 2023 年的收购价为 6.8 亿美元，三年间估值翻逾 5 倍。

其他：百事于 2025 年 5 月完成收购益生元汽水品牌 poppi，总价 19.5 亿美元（含约 3 亿美元预期现金税收收益，净收购价约 16.5 亿美元，另含业绩对赌条款）；拜耳 2020 年 8 月收购 Care/of 的 70% 股权，个性化营养 DTC 模式经营承压，美国业务于 2025 年停止运营；费列罗 2026 年 8 月 14 日宣布收购美国健康早餐品牌 Purely Elizabeth，金额未正式披露，Forbes 估算超过 8.5 亿美元，预计数月内完成。

趋势小结

报告认为，近年并购正从传统维生素、普通膳食补充剂向高端化、科学化、功能化和精准化升级，标的集中在四类资产：临床/科学背书的高端 VMS（Thorne、Nutrafol、健美生、澳佳宝）；个性化营养与数字健康（Care/of）；功能营养新剂型（Grüns、SmartyPants、Liquid I.V.、poppi）；蛋白、肠道健康与完整营养等新增长赛道（Orgain、Huel、yfood、MADE Group、Akkermansia）。

① 从“大众 VMS”到“高端科学营养”：押注高溢价、有临床背书的资产。

② 从“单一产品”到“能力平台”：买的是科学成分/技术、临床证据、高端品牌、专业渠道和消费者数据的组合。

③ 从“传统剂型”到“新剂型/新场景”：软糖、补水、功能饮料、代餐等更贴近年轻消费者。

④ 从“西方主场”到“全球卡位”：麒麟连买澳佳宝、芳珂、健美生，达能收购澳洲 MADE 与比利时 Akkermansia，亚太与新兴市场成为布局重点。

另一个观察是“买了又卖”：雀巢 2021 年以 57.5 亿美元买入 Bountiful 核心品牌，2026 年即以 10 亿美元出售其中的大众品牌；拜耳的 Care/of 亦因经营承压关停。需要注意的是，两笔交易的范围并不相同（10 亿美元仅涉及 7 个大众品牌，Solgar 等高端品牌保留），不宜直接等同比较。这提示科学营养并购同样存在风险，标的能否带来持续协同与增长，才是判断成败的关键。

口径说明

主要来源为各公司官方新闻稿与公告、上市公司公告，以及 Reuters、Bloomberg、Forbes、Financial Times 等媒体报道。外币金额保留原币种，美元换算仅作横向比较参考；表中时间为交易宣布或完成时间；“当前状态”以截至 2026 年 9 月 11 日的公开信息为准。原报告注明“仅供内部参考”。

编者注：关于宝洁收购 Thorne，据 CNBC 2026 年 8 月 4 日报道，宝洁将以 38 亿美元收购 Thorne，该消息由宝洁 CEO 向 CNBC 披露。Thorne 此前于 2023 年由 L Catterton 以约 6.8 亿美元收购；在宝洁宣布前，Reuters 曾报道 Thorne 正探索以最高约 40 亿美元估值出售。

Nestlé has agreed to sell seven of its mainstream vitamin, mineral, and supplement (VMS) brands — Nature’s Bounty, Osteo Bi-Flex, Ester-C, Gard, Nuun, Puritan’s Pride, and Sisu — to private equity firm Yellow Wood Partners for $1 billion. The deal also covers the associated US private-label supplements business and dedicated manufacturing and distribution operations. It illustrates how far the market has shifted away from legacy, mass-market supplement brands toward premium, science-led ones.

A Deal That Raised Eyebrows

Nestlé’s mainstream VMS portfolio, known internally as its Holistic Health business, generated $1.2 billion in sales in 2025, so the $1 billion price values the business at well under 1x sales. Industry strategist and former Nutrition Business Journal editor Marc Brush characterized the deal as falling into the “distressed assets” category. He noted that the strategic review took more than a year and that the price is a fraction of the $5.75 billion Nestlé originally paid for the bulk of these brands, along with premium brand Solgar, in its 2021 purchase of The Bountiful Company.

Doubling Down on Premium, Science-Led Brands

Nestlé’s leadership framed the divestiture as a deliberate move to concentrate resources where the company sees its strongest competitive advantage, citing the stronger performance of its premium brands Solgar and Pure Encapsulations. The company said the remaining mainstream brands are likely to benefit from more focused, dedicated ownership under Yellow Wood rather than sitting within Nestlé’s broader portfolio. The transaction remains subject to regulatory approval and is expected to close in the first half of 2027.

What This Signals for the Broader Market

The deal offers a quantifiable data point for a trend many in the industry have observed anecdotally: mainstream and budget VMS brands are losing ground to premium, science-backed, and clinically substantiated positioning, even among large multinational owners with significant scale advantages. For companies and investors assessing brand portfolio strategy, it is a useful benchmark for how the market currently values legacy mass-market supplement assets relative to premium ones — and a signal that “science-led” positioning is increasingly a prerequisite for long-term brand value, not just a marketing preference.

What began as a supplement-industry response to the side effects of GLP-1 weight-loss medications is fast becoming a cross-industry contest. Big Food, ingredient suppliers, dedicated supplement brands, and pharmaceutical companies are now all targeting the same emerging consumer need.

Nestlé’s Entry Validates — and Intensifies — the Opportunity

In 2024, Nestlé Health Science launched a GLP-1 nutrition support platform addressing muscle preservation, gut health, micronutrient intake, hydration, skin and hair health, and weight-rebound management — the secondary nutritional concerns that can accompany GLP-1 medication use. According to Scott Dicker, senior director of market insights, the supplement industry was historically the first to identify these needs and develop targeted solutions. Nestlé’s entry both validates that early work and raises the competitive bar, given the company’s scale and resources.

A Widening Ecosystem of Players

Nestlé is not alone. Biosolutions company Novonesis and pharmaceutical maker Novo Nordisk have partnered to study whether microbiome-targeted supplements can enhance the effectiveness of GLP-1 medications themselves, rather than simply managing side effects — a notable case of a pharma company engaging with the supplement and ingredient space rather than treating it as a threat. It reflects a broader reframing across food and pharma: instead of seeing GLP-1 drugs as a threat to food and supplement consumption, companies increasingly treat the nutritional aftereffects of GLP-1-driven weight loss as a distinct product-development opportunity.

From Niche Trend to Broader Nutrition Ecosystem

According to Dicker, investment by food, ingredient, supplement, and pharmaceutical companies around the same consumer need is typically a sign that an opportunity has matured beyond a niche trend into an established category. He noted that the entry of major food and health companies could expand the overall market rather than simply redistribute existing demand — good news for ingredient suppliers, but also a signal that competitive intensity and the need for differentiation will only increase.

Relevance for Product and Ingredient Strategy

For companies tracking this space, the key strategic question is shifting from “should we enter GLP-1-companion nutrition” to “how do we differentiate within an increasingly crowded field.” Muscle preservation and gut health during rapid weight loss appear to be emerging as particularly contested areas, worth close monitoring for ingredient positioning and clinical substantiation opportunities.

Beauty-from-within products now rank second only to general health among APAC’s vitamin and dietary supplement categories, according to Euromonitor Consumer Health 2026 data cited by Sirio Pharma, a nutraceutical contract development and manufacturing organization (CDMO). At the recent Growth Asia Summit, the company outlined how it is approaching this fast-growing but increasingly crowded category.

Ingredient Trends: Beyond Collagen and Hyaluronic Acid

Collagen and hyaluronic acid remain the category’s staple ingredients, but Sirio’s senior ingredient innovation scientist Dr. Shanlu Liang noted growing consumer and formulator interest in vitamin A, vitamin C, and traditional herbal ingredients as complementary or differentiating actives. Australia, New Zealand, Thailand, and Indonesia show particularly strong beauty-from-within demand.

The Collagen Peptide Standardization Problem

One of the sector’s central challenges, according to Dr. Liang, is homogeneous competition combined with the lack of a true gold standard for evaluating ingredients such as collagen peptides. Dr. Liang argued that the common assumption that smaller-molecular-weight peptides are inherently better absorbed is not necessarily accurate, and made the case for characterizing peptides beyond molecular weight alone, through more precise separation and functional validation of specific peptide sequences.

Format Innovation: Gummies at Scale

Beyond ingredient selection, Sirio is working on delivering functional ingredients in differentiated formats at optimized dosages, with gummies a particularly active area. The company says it has developed technology that allows a single gummy to carry 1,500 mg of collagen — described as two to five times the typical loading for this format — addressing the gummy’s traditional limitation of low active-ingredient payload compared with capsules or powders.

Relevance for APAC Formulation Strategy

For companies developing or sourcing oral beauty products for APAC, the combination of peptide-level ingredient differentiation and high-payload gummy formats is a concrete example of how CDMOs are helping brands move beyond category homogeneity. With the category growing rapidly and competition intensifying, ingredient specificity and format innovation both appear likely to become more important levers for differentiation than the inclusion of collagen or hyaluronic acid alone as a claims basis.

Supplement advertising has long faced scrutiny over influencer marketing, but a recent investigation has surfaced a new twist: AI-generated personas — presented as doctors, health authorities, and even ordinary satisfied customers describing personal experiences — are being used to sell supplements, and none of them are real people.

A Familiar Risk, Amplified by New Technology

According to legal expert Marcus, AI-generated personas that project professional authority warrant particular attention in health and wellness advertising, because consumers in this category often rely heavily on perceived expertise. The central legal and ethical question for advertisers, she suggested, is whether a reasonable consumer could plausibly believe a synthetic persona has qualifications, experience, or knowledge that it does not actually have. If there is meaningful risk of that confusion, the approach should be reconsidered altogether.

Not a New Problem, But a More Scalable One

The concern builds on well-documented issues with human influencer marketing in supplements. Prior research analyzing Instagram posts from European influencers found that a majority of intensively advertised vitamin and mineral supplements exceeded recommended maximum daily intake amounts, frequently without disclosure of overdose risks or side effects. AI-generated personas do not introduce a fundamentally new category of harm — false expertise, exaggerated claims, and undisclosed risks were already problems with human influencers — but they substantially lower the cost and effort of producing large volumes of seemingly authoritative, trust-building content.

Regulatory Response Still Catching Up

Existing frameworks, such as the UK influencer marketing code of conduct co-owned by the Incorporated Society of British Advertisers, were largely designed around human influencers disclosing paid partnerships and are still adapting to AI-generated content. Some jurisdictions have begun to legislate more directly: a 2025 New York law requires advertisement producers to disclose when AI-generated synthetic performers are used, though comprehensive US federal regulation specifically addressing AI-generated advertising remains absent as of this writing.

Relevance for Brand and Compliance Strategy

For supplement brands and their marketing partners, this is a clear signal to proactively audit any AI-generated content — including personas, testimonials, or apparent expert endorsements — well ahead of regulatory enforcement catching up with the technology. Brands relying on third-party agencies or influencer networks should also confirm that none of the “experts” or “customers” in campaign content are AI-generated without clear, prominent disclosure, given the reputational and legal exposure.

The US Food and Drug Administration’s proposal to make Generally Recognized As Safe (GRAS) notifications mandatory, rather than voluntary, is meant to close a longstanding information gap in food ingredient oversight. But it raises a more immediate practical question for the industry: does the FDA have the staff and resources to handle the resulting surge in submissions?

The Scale of the Gap the Rule Is Meant to Close

Under a 1958 amendment to the Federal Food, Drug, and Cosmetic Act, companies may introduce food substances without direct FDA authorization if qualified experts determine the substances are generally recognized as safe under their intended conditions of use — the so-called “self-GRAS” pathway. Companies have voluntarily notified FDA of more than 1,200 ingredients they determined to be GRAS, but consultancy Manatt estimates that at least 1,000 substances now in the food supply have never been submitted. The proposed rule would close that visibility gap by requiring notification going forward. As several commentators have pointed out, however, it addresses the problem only partially, since core questions about legal authority and implementation capacity remain unresolved.

A Sharp Increase in Expected Volume

According to Natural Products Association president Daniel Fabricant, the FDA currently receives roughly 50 voluntary GRAS notices a year; under a mandatory system, that could rise into the hundreds or even thousands. The Consumer Healthcare Products Association and the Council for Responsible Nutrition have each raised concerns that such an increase could strain an already resource-constrained agency, potentially causing significant delays in ingredient review and market entry.

Cost and Staffing Concerns

FDA’s own estimate puts the cost of the proposed rule at approximately $89.6 million, with a high-end estimate of $210 million and annualized costs of roughly $10.5 million to $24.6 million. These estimates come against a backdrop of substantial FDA staffing reductions, reported at 3,850 to 4,300 employees lost since 2025. That leaves open where the resources to process more submissions would come from, particularly given the one-time influx expected from a “streamlined pathway” for previously self-determined GRAS ingredients that were never formally submitted.

Relevance for Regulatory Strategy

Companies with new or pending self-GRAS determinations should monitor this proposal closely, both for its substantive requirements and for what it may mean for review timelines. If mandatory notification is finalized without a matching increase in FDA capacity, companies should be prepared for possibly longer waits for “no questions” letters than the multi-year timeline already in place.

See also: S-03-19 (in Chinese) on the US HHS proposal to make GRAS notification mandatory.

美国卫生与公众服务部（HHS，U.S. Department of Health and Human Services）于10日公布GRAS（Generally Recognized as Safe，一般公认安全）规则修正案。该修正案拟将向美国食品药品监督管理局（FDA）提交通知由现行自愿性改为强制性，并要求重新审视既有的自我确认GRAS，在美国业界引发担忧。

据介绍，新规则旨在推动政府对食品成分监管的现代化，为未来营养政策奠立更坚实的科学基础；通过强化监管，要求企业就GRAS作出适当通知与判断。为提升透明度，提交的通知将向社会公开，预计年内作出最终决定。

此外，规则要求制造商就已上市流通的自我确认GRAS成分提交最低限度的电子信息。借此，FDA在提升对进入食品供应链成分的监管能力的同时，也设置了减轻制造商负担的机制；对既有成分则要求采用简化提交方式。

另见本刊 S-03-07（英文）：FDA 拟强制 GRAS 通知，机构资源能否承受。

ADM is investing more than $16 million to expand naturally derived color production at its Boone County, Kentucky facility. The expansion adds about 14,000 sq ft of manufacturing space and increases capacity for both liquid natural-color systems and dry blends, with commissioning targeted for early 2027. A separate, nearby investment in Erlanger of $26 million is also referenced.

Reformulation Pressure Drives Demand

The investment reflects growing reformulation pressure, as brands respond to regulatory scrutiny of synthetic dyes and consumer preference for more recognizable ingredient labels. ADM cites an estimated $1 billion North American opportunity associated with converting from artificial to natural colors.

Natural Pigments Are Operationally Demanding

The article stresses that natural pigments are more demanding to work with than synthetic dyes. Shade consistency, pH and heat stability, shelf life, sourcing variability, and scale-up reliability are all important commercialization challenges.

Relevance to BGG

The move supports the strategic relevance of BGG’s natural carotenoid and microalgae pigment portfolio. The opportunity is not simply “natural versus synthetic”: customers increasingly need stable, reproducible, and scalable color systems. BGG may therefore wish to emphasize application performance, formulation systems, and supply reliability alongside pigment origin and purity.

GOED’s 2026 Ingredient Market Report shows a divergence between global omega-3 ingredient volume and value in 2025. EPA+DHA ingredient volume rose while total market value fell. The report attributes this mainly to price normalization after the earlier El Niño-related disruption to Peruvian anchovy oil supply.

Key Figures

Global EPA+DHA ingredient volume in 2025 was approximately 136,000 metric tons, up 2.6% year over year. The ingredient market was worth approximately $2.53 billion, down 4.3%. The report covers six finished-product categories, with forecasts through 2028.

Where Growth Is Coming From

The United States and Europe remain the largest markets by volume, while China is identified as the fastest-growing, linked to a more developed supplement market and expanding pet-nutrition demand. Pharmaceutical and infant-formula volumes were comparatively flat.

Risks Through 2028

The report highlights supply-chain concentration, low inventory buffers, geopolitical instability, and protectionist trade policies as risks through 2028.

Relevance to BGG

The data are relevant to BGG’s microalgae EPA strategy. Volume growth does not necessarily translate into higher raw-material value, so algae-derived EPA may need a differentiated value proposition rather than relying on overall omega-3 market growth. Potential advantages include supply diversification, non-fish origin, controlled composition, and targeted high-value applications.

FDA has opened a request for information seeking public input on how the US botanical-drug development framework could be improved. The definition discussed includes products derived from plants, algae, and macroscopic fungi, which makes the topic directly relevant to algae-derived active ingredients. Comments are due November 3, 2026.

What FDA Is Asking

The agency is seeking feedback on obstacles in botanical R&D, modernization of its 2016 Botanical Drug Development guidance, quality benchmarks, characterization of complex mixtures, clinical-trial design, and the potential use of real-world evidence.

Industry Concerns

Industry participants have raised concerns about inconsistent application of the pathway across review divisions, batch-to-batch variability, and investment risk. The article states that only four botanical products have cleared FDA prescription-drug pathways. Main issues include complex-mixture characterization, potency, quality control, batch consistency, clinical design, and real-world evidence.

US–EU Comparison

The article also notes a joint FDA-EMA workshop, scheduled for September 25, 2026 (a date that falls before this issue’s release; readers may wish to check the outcome), in Amsterdam and online, to compare US and European approaches to herbal medicinal and botanical drug development.

Relevance to BGG

This may be strategically important for BGG because it points to a potential long-term pathway for selected algae-derived actives to move beyond supplement positioning. For compounds with strong mechanistic and clinical evidence, BGG may wish to monitor how FDA evolves its requirements for complex mixtures, identity, potency, batch consistency, and clinical characterization.

近日，ZMUni中贸合规中心梳理并发布了2026年8月全球食品法规动态，覆盖中国、美国、欧盟、加拿大、英国、澳新、新加坡及中国台湾地区，内容涉及新食品原料、食品添加剂、婴幼儿配方食品、有机认证、农兽药管理、食品标识等多个领域，为食品生产及进出口企业提供合规预警。

一、中国：三新食品领域多项项目推进

2026年8月，国家卫生健康委发布三新食品审查动态，包含新食品原料受理、食品添加剂新品种受理、新食品原料延期等，具体如下：

新食品原料——新增受理3例：管花肉苁蓉提取物、干制紫皮石斛叶、干制紫皮石斛花。

食品添加剂新品种——新增审查意见告知3例：乳糖酶（β-半乳糖苷酶）、桂花耳糖脂、甜菊糖苷RM。

食品添加剂新品种——新增受理1例：β-胡萝卜素。

特殊食品板块，国家食品安全检验检测技术研究中心发布6条婴幼儿配方乳粉产品配方注册实务问答，聚焦新配方注册、变更注册实操问题。市场监管总局就《特定全营养配方食品临床试验技术指导原则（肿瘤）》等11项国标及1项修改单向社会征求意见。

标准与监管政策同步落地：市场监管总局正式发布新版《有机产品认证目录》，是有机认证受理申请的核心依据；农业农村部更新《禁限用农药名录、禁停用兽药名录》。针对食品标签监管痛点，总局发布《食品标识监督管理办法》35项官方问答，覆盖生产日期、保质期、保健食品标识等实务问题。

口岸监管数据显示，2026年7月全国海关共检出487批次不合格食品未准入境，环比下降11%，同比小幅上升2%。中国台湾食药署8月出台菊粉原料使用及标示新规，发布即生效，明确该原料生产工艺、质量规格与标签要求。

二、国际层面：多项制度调整落地或提出

美国

FDA于8月提出GRAS制度修订拟议规则，计划将原有自愿通知改为强制通知，提高物质安全结论公开透明度，并对过往企业自行判定的self-GRAS物质设置信息提交通道。意见征集截止至2026年12月9日。该规则若最终落地，将改变美国食品原料行业的合规模式。

欧盟

8月落地两项重要法规：其一，修订卡拉胶、瓜尔胶、黄原胶等7种胶体添加剂的规格与使用条件，明确幼儿乳基饮料、特医食品的最大使用限量；其二，新增婴幼儿食品中呋喃及甲基呋喃的限量管控——加工谷物类婴幼儿食品限值40 μg/kg，乳基、果基婴幼儿食品限值30 μg/kg，其余婴幼儿食品限值80 μg/kg。该法规2026年8月生效，限量要求自2028年1月1日起正式执行。

加拿大

完成两项食品监管更新：（1）将Sidr果肉粉、VITACEL®柑橘纤维认定为“非新（Non-Novel）食品原料”；（2）修改补充剂成分清单，将含咖啡因补充饮料的果汁占比上限放宽至30%，并修正L-天冬酰胺相关条目。

英国

FSA公布多项食品原料安全评估结果，涉及3-岩藻糖基乳糖、裂殖壶菌油、CBD新食品申请。

澳大利亚和新西兰

FSANZ批准葡萄酒加工用壳聚糖及多种酶制剂作为加工助剂。

新加坡

新加坡食品局（SFA）更新《List of Approved Novel Foods》，将由Neurospora crassa OR-1生产的菌蛋白产品“Noushroom”纳入批准新食品清单，设定蛋白质≥45%及重金属、微生物管控指标。该项目于2026年8月14日加入新食品批准清单。

2026年8月14日，中国医药保健品进出口商会发布数据显示，2026年上半年中国膳食营养补充剂行业呈现“出口稳增、进口回调、逆差收窄”的特征。上半年进出口总额为62.16亿美元，其中出口额23.59亿美元，同比增长4.91%；进口额38.57亿美元，同比下降2.98%。贸易逆差为14.98亿美元，较2025年同期明显收窄，结束了连续三年逆差扩大的趋势。

出口：美国重夺第一大市场

美国以3.88亿美元的金额重夺中国第一大出口市场地位，同比增长37.32%。对东盟十国出口总额为5.45亿美元，同比下降17.87%；对欧盟27国出口总额为2.61亿美元，同比增长16.31%。从国内省市看，山东省以3.95亿美元超越江苏省跃居全国首位，同比增长27.30%。鱼油类产品出口止跌回升，出口额2.51亿美元，同比增长24.25%。

进口：秘鲁增长突出，鱼油进口大增

美国仍以6.87亿美元保持第一大进口来源国地位，但同比下降16.31%；自德国进口5.40亿美元，同比下降19.18%。秘鲁表现最为突出，进口额从2025年上半年的0.62亿美元升至1.75亿美元，同比增长182.80%。鱼油类产品进口额3.84亿美元，同比大幅增长60.07%，成为增速最突出的品类。

电商渠道

2026年上半年线上销售额达672.8亿元人民币。抖音平台（含抖音全球购）以34.1%的份额跃居首位，淘天集团30.3%退居第二。鱼油品类线上销售额同比增长44.91%，表现最为突出。成人产品销售额同比大增70.78%，显示精准营养和细分人群产品成为重要增长方向。

日本富士经济于12日公布2026年清凉饮料市场预测：市场规模将同比增长7.1%，达6.2853万亿日元。

该预测汇总于《2026年清凉饮料营销要览》（2026 Soft Drink Marketing Handbook）。调查对象包括果蔬饮料、碳酸饮料、乳性饮料、咖啡饮料、茶饮料、矿泉水和功能性饮料等。

报告指出，尽管2026年日本存在涨价抑制消费的担忧，但茶饮料和矿泉水类国民品牌通过与自有品牌（PB，private brand）实现商品差异化，仍被期待增长。饮用型酸奶（Drink yogurt）领域则持续以新健康功能作为附加价值开发商品，各企业借助新品开发与容器容量策略刺激需求，预计市场将突破6万亿日元。

就饮用型酸奶而言，企业一方面把握免疫对策类商品的需求，另一方面推出以女性为中心、瞄准铁元素摄取需求的产品，用户群体有望扩大；该品类市场预计同比增长4.7%，达1633亿日元。

日本SS制药于1日发售功能性标示食品“Driel Your Rhythm Beauty”。产品配合了功能性成分GABA（γ-氨基丁酸）、香蜂草来源的佩罗苷（Peroside）、香蜂草来源的异槲皮苷（Isoquercitrin）以及大米来源的葡萄糖神经酰胺（Glucosylceramide）。

据产品标示，其宣称包括“改善睡眠质量”“维持肌肤弹性、守护肌肤健康”。片剂为粉色，并调制成玫瑰香气，推出6日装与14日装两种规格。

日本国立环境研究所环境风险与健康领域的谷口优、东京都健康长寿医疗研究中心和东京大学等研究团队于18日发表研究结果：如果与犬同住的老年人数量增加，四年内或可减少约5920亿日元医疗费用。

研究以日本11224名居家老年人为对象，进行了7.5年追踪，将对象分为“正在饲养犬”“过去曾饲养犬”和“无饲养经验”三组，解析“正在饲养犬”及“过去曾饲养犬”与相关健康结果的关联。

结果显示，与从未饲养犬者相比，正在饲养犬者需要护理的痴呆症发病风险低48%。

研究团队还假设犬饲养率为13.4%，进行了预算影响分析：计入家庭因饲养犬产生的支出，日本社会整体追加费用约4.63万亿日元；而从公共支付者视角看，四年医疗与护理费用有望减少约5920亿日元。

日本富士化学工业（Fuji Chemical Industries）面向东南亚的受托生产项目正在扩大，以泰国、越南、印度尼西亚、菲律宾为中心，符合清真认证的喷雾干燥项目不断增加。

该公司依托逾百年的提取与粉末化技术，开展植物来源原料的受托制造。除FSSC 22000体系认证外，还建立了清真（Halal）与犹太洁食（Kosher）认证体系。今年公司完成了美国食品药品监督管理局（FDA）设施注册，面向北美的受托订单亦稳步推进，计划海外拓展的客户咨询保持坚挺。

在化妆品原料领域，富士的主力喷雾干燥机（spray dryer）维持高开工率，并与日本北关东地区合作方协作强化供应体系。

此外，该公司独有的梅醋来源素材“梅蛋白聚糖（Ume Proteoglycan，YPG90）”已取得清真认证，海外询盘增加；在泰国市场，除美容用途外，对关节健康维持领域的关注也在上升。

美国Biovivo Science正面向日本市场推出有机锯叶棕提取物及粉末产品。该公司自8月起已向日本市场销售蔓越莓（Cranberry）、瓜拉那（Guarana）、针叶樱桃（Acerola）等超级水果原料。

该公司与美国佛罗里达州种植农户直接交易，通过定期采购建立具有价格竞争力的稳定供应体系。锯叶棕果实提取物由其自营工厂制造，该工厂已获得cGMP（Current Good Manufacturing Practice，现行药品生产质量管理规范）认证，采用超临界二氧化碳萃取及乙醇萃取工艺；产品阵容涵盖总脂肪酸含量15%～85%的锯叶棕油。

英富曼集团（Informa Group）旗下美国行业杂志《New Hope Network》于6日出版《Condition Specific Report 2026》，公布2025年美国健身与能量补充剂（Fitness & energy supplement）市场同比增长7.9%，扩大至132.2亿美元。

“健身与能量（Fitness & Energy）”类别涵盖运动营养成分、草本、代餐产品、能量支援产品等，占2025年整体补充剂市场的7.1%。

该杂志认为，市场增长的背景在于该类别已不止于流行，而成为日常生活的核心类别。预计到2029年，市场规模将增长至180亿美元。

Here is a look back and a look ahead for the International Division as we move into a busy final quarter of 2026.

International Sales Conference (August 2026)

The team gathered for the division’s sales conference to align on key sales initiatives, leadership development and strategy for market growth.

SupplySide Global Exhibition (late October)

BGG will exhibit at North America’s premier health and nutrition event for ingredient innovation and networking. The focus will be BGG’s “Dream Team” — ApplePhenon®, AstaZine® and TheraPrimE® — which the team will present around top consumer interests in weight management, mental health, and positive aging and longevity.

2025年8月6日，烟台。中宠股份全球研发创新服务中心焕新启航，旗下全球联合研究创新中心正式揭牌。BGG 与帝斯曼、奇华顿、诺和新元等企业同步入驻。

据介绍，在这份合作名单中，BGG 是唯一的中国企业，也是唯一专注天然功能成分的共研核心方。此次落地的“中宠股份 × BGG 宠物天然成分功效研究联创项目”，是中国宠物食品龙头与中国天然成分企业在全球创新赛道上的一次携手。

一、双龙头联袂：两大赛道，双向赋能

中宠股份业务覆盖宠物全品类食品，产品销往 50 余个国家和地区，已形成全球化的生产、研发、销售一体化供应链。此次升级全球研发创新服务中心、搭建联合科研平台，是中宠在高端化、科技化、全球化方向上的战略布局。

BGG 深耕天然功效成分领域三十年，坚持全产业链自研自产，形成从专属原料种植、精密萃取加工、稳态改性技术到临床配方研发的完整体系。集团在全球布局六大生产基地，服务多家世界 500 强企业，拥有 30 余项国际专利、20 余项临床研究成果和 80 余篇科研论文，并培育出 5 项全球市占率位居前三的核心原料。

双方的合作并非简单的供需关系：中宠股份提供终端市场洞察、全链条产业平台与规模化落地能力；BGG 提供经临床研究验证的天然功效成分体系、研发技术与全产业链质控能力，以循证科研支持宠物营养产业升级，共同拓展天然成分在宠物领域的应用边界。

二、科研破界：“人宠同源”研发思路

揭牌仪式后，首届 CPF 宠物食品技术创新交流论坛同步举行。BGG 市场总监张培楠受邀出席并作主题演讲，介绍 BGG 在宠物健康赛道的研发理念与技术布局。

基于三十年人体营养研究积累，BGG 提出“人宠同源、科学共护”的研发思路。据介绍，宠物常见的关节退化、皮肤炎症、口腔问题和代谢紊乱等，与人体在病理机制上存在较多共通之处；BGG 因此将已有人体临床研究基础的成分体系，适配到宠物健康管理场景，形成四类宠物专属方案。

方案聚焦宠物的核心健康需求：黑豆皮提取物 CyaniMax® 与杜仲提取物面向关节养护，生育三烯酚面向毛发健康，苹果多酚面向口腔护理与体重管理两个方向。据介绍，所有核心原料均符合中国饲料原料合规标准。相关研发方向已与中国农业大学开展产学研合作，并启动专项动物临床试验，以研究数据支持后续产品开发。

三、联合创新，共同前行

全球联合研究创新中心的揭牌，是 BGG 与中宠股份深化战略合作的新起点。未来双方将依托联合科研平台，在天然成分的宠物应用研发、临床验证、创新产品转化和市场落地等方面协同，结合中宠的全球渠道、规模化生产与终端市场优势，以及 BGG 的全产业链自研能力和临床研究积累，推动一批有科学依据、有市场竞争力的宠物健康新品落地。

文章指出，全球宠物营养市场正进入更精细化、标准化的阶段，天然配方、明确功效、科学循证成为行业升级的方向，监管体系也在持续规范，竞争正从概念营销与低价竞争转向技术创新、品质升级与实证功效。BGG 表示，将继续与中宠股份携手，以临床研究为基石、以天然安全为底色、以联合创新为引擎，深耕宠物营养赛道。

近期，在产业媒体《食品万里行》发起的“全球宠物食品创客”评选中，BGG 凭借“黑豆皮宠物关节创新原料”和“宠物减重纯天然精准营养方案”两项成果，获得“营养原料奖”。

同期举办的第二届宠物健康、营养食品技术及应用创新论坛上，BGG 市场总监张培楠作了题为《深耕三十载：基于临床研究的天然功能营养》的主题演讲，分享天然功效成分在宠物健康领域的研发实践。

文章指出，随着宠物行业发展，市场对原料的要求已经从“概念性添加”转向“可验证的实际功效”，BGG 坚持以临床数据为依据，把经过科学研究的天然成分应用于宠物营养场景。

一、两项成果获“营养原料奖”

《食品万里行》“全球宠物食品创客”评选，旨在表彰在原料创新、科学验证、产业落地等方面表现突出的企业与产品。BGG 此次获奖的两项成果为：

1. 宠物黑豆皮关节创新原料：面向宠物关节退行性病变。

2. 宠物减重纯天然精准营养方案：面向宠物肥胖及代谢紊乱，采用“控吸收 + 促燃脂”协同思路。

据介绍，两项成果均有较明确的作用机制和实验数据支持，并符合国内饲料原料合规要求。

二、行业论坛：基于临床研究的天然功能营养

张培楠在演讲中介绍，BGG 依托自主可控的全产业链与临床研究体系，为全球 500 强企业提供产品与技术服务：已培育 5 项全球市占率位居前三的核心原料，其中包括日本市场占有率过半的单品和美国市场规模超 1 亿美元的商业化产品；拥有 30 余项国际专利、20 余项临床研究成果、80 余篇科研论文，在全球布局六大生产基地。

他提出，可以从“人宠病理机制具有较高共通性”的视角研究宠物健康问题：皮肤炎症、关节退行性改变、肥胖代谢异常等，其底层病理通路与人类有较多相似之处，但物种间在代谢与生理上也存在固有差异。因此 BGG 的研发路径是：将经过人体临床研究的天然功效物质，再通过专项宠物临床研究进行适配，实现向宠物健康场景的转化。

三、获奖原料解读①：黑豆皮提取物 CyaniMax®

关节退行性病变是中老年宠物较常见的健康问题之一。滑膜炎症、软骨磨损、软骨降解酶升高和氧化应激加剧，被认为是宠物关节损伤退化的四个主要因素。BGG 的黑豆皮提取物 CyaniMax® 从抗炎、抗氧化和软骨保护三个方向开展研究。据介绍，现有实验结果包括：

· 关节肿胀：在白陶土-鹿角菜胶诱导的大鼠膝关节炎模型中，第 7 天黑豆皮提取物组的关节肿胀度较模型对照组下降 54%，该模型中缓解肿胀的效果优于氨糖。

· 炎症与软骨：黑豆皮提取物与组织炎症水平降低 38.5% 相关；与氨糖复配时，软骨侵蚀评分降低 53.8%、组织病理学总评分降低 44.7% 与之相关（动物模型）。

· 合规路径：该原料对应《饲料原料目录》中的“大豆皮粗提物”（原料编号 2.3.8）。

以 CyaniMax® 为核心的宠物专项临床试验，目前正与中国农业大学联合开展。上述结果来自动物模型，尚不能直接等同于宠物的实际使用效果。

获奖原料解读②：宠物减重纯天然精准营养方案

宠物肥胖不仅是体态问题，也与关节损伤、代谢障碍、心血管疾病等健康风险相关。BGG 的宠物减重方案采用“控吸收 + 促燃脂”的双重思路，从“收入”和“支出”两端着手：

1. 控制“收入”：作用于消化系统，减少脂类和碳水化合物的吸收，并与餐后血糖峰值降低相关，从而减少脂肪合成的原料供应。

2. 增加“支出”：通过调控线粒体核心蛋白表达水平、上调脂肪分解关键酶活性，与提升静息状态下的能量消耗、促进脂肪代谢相关。

BGG 认为，抑制热量吸收与促进脂肪分解相结合，可形成能量负平衡，相较单一成分思路有望更有利于体重管理。相关配方的宠物临床试验目前正在推进中。

四、为什么是 BGG：获奖背后的能力

1. 合规保障：BGG 宠物业务线核心原料均符合国内饲料原料法规标准，产品方向覆盖关节养护、美毛护肤、肠胃调理、口腔护理、泪痕管控、体重代谢管理、免疫调节、抗衰老八个方面，为合作品牌提供合规的产品开发路径。

2. 科研为本：从生育三烯酚宠物毛发养护研究、苹果多酚抑制牙菌斑与口臭的随机对照试验，到黑豆皮关节保护动物模型试验，BGG 的准则是每一项功效宣称都要有对应的试验数据支持。

3. 全球供应保障：依托六大生产基地和完整自主产业链，具备供应链协同与稳定供货能力。

奖项代表行业认可，也意味着技术创新的责任。BGG 表示，将继续以天然成分、临床验证、安全有效的研发理念，与国内宠物食品上下游伙伴合作，把宠物功能性原料转化为落地产品，守护伴侣动物的健康与陪伴。

体重变化和肝脏脂质沉积看似属于不同问题，背后却可能连着同一张代谢网络。岩藻黄质（Fucoxanthin，亦称岩藻黄素）是这张网络中受到关注的海洋成分之一。本文围绕四个问题展开：UCP1 如何影响能量消耗；脂肪细胞为何像“新仓库”；炎症与氧化应激如何影响代谢；肝脏如何合成、氧化和输出脂质。

写在前面：从一张代谢网络，理解体重与肝脏脂质

提到体重管理，很多人首先想到体重秤上的数字；提到肝脏健康，人们关注的可能是转氨酶、血脂，或体检报告上的“脂肪沉积”提示。这些指标并不完全独立，因为脂肪组织、肝脏和线粒体共同参与人体的能量与脂质代谢。

不妨把人体想象成一座每天运转的“能源城市”：食物是城市获得的能源，摄入的营养物质可直接供能，也可参与脂质合成并储存在脂肪组织（“仓库”）中；肝脏是脂质合成、分解、回收和转运输出的核心调度中心；线粒体则像分布在细胞中的小型发电站。

当能量摄入长期超过消耗，脂肪组织逐渐扩张；如果“仓库”长期高负荷，多余的膳食脂质和脂肪组织释放的脂肪酸也可能流向肝脏，增加肝脏的代谢压力。因此，代谢营养研究不应只看体重是否变化，还要关注：能量在储存与消耗之间如何分配？脂肪细胞如何形成并储存脂质？肝脏如何完成脂质的合成、氧化和输出？炎症与氧化应激为什么会让代谢问题更复杂？

在这样的背景下，来自海洋褐藻的天然成分岩藻黄质逐渐进入科研人员和营养产品开发者的视野。

一、岩藻黄质的基础概念

岩藻黄质是一种天然类胡萝卜素，广泛存在于海带、裙带菜等褐藻中，也是褐藻呈现黄褐色的重要天然色素之一。它在代谢研究中受到关注，主要因为在多种代谢模型中表现出调节作用。

与人们熟悉的“抗氧化成分”不同，岩藻黄质的研究范围还延伸到能量消耗、脂肪细胞形成、脂质储存、炎症与氧化应激，以及肝脏脂质代谢。本文要回答的是它为什么值得研究，而不是把它包装成一个“神奇成分”。

二、路径一：UCP1 与“产热开关”

UCP1（解偶联蛋白 1）是参与棕色和米色脂肪产热的线粒体蛋白，位于线粒体内膜。通常情况下，营养物质氧化产生的能量主要转化为 ATP，供细胞直接使用；UCP1 则像一个“产热开关”，使一部分本可用于生产 ATP 的能量以热的形式散发出去。这一过程称为非颤抖性产热，即不依赖骨骼肌颤抖的产热。

人体的脂肪并不完全相同：白色脂肪更像仓库，主要储存能量；棕色和米色脂肪更像小型锅炉房，富含线粒体，更擅长通过 UCP1 产热。动物研究发现，褐藻脂质及其岩藻黄质组分可降低肥胖和糖尿病模型小鼠的白色脂肪组织重量，并提高其中 UCP1 的表达[1]，提示岩藻黄质可能影响脂肪组织的能量利用方式，使部分脂肪组织表现出更多“产热型”特征。

小结：UCP1 相关研究关注的是能量的分配方式——营养物质氧化产生的能量，有多少用于 ATP 合成，有多少直接以热量消耗。

三、路径二：脂肪细胞形成与脂质储存

脂肪组织扩张既可能来自成熟脂肪细胞体积增大，也可能涉及新脂肪细胞的形成。人体中有一类尚未成熟的“前脂肪细胞”，在特定信号作用下可能分化为成熟脂肪细胞并开始储存脂质——好比城市不只把货物塞进旧仓库，还可能不断批准建设新仓库。

PPARγ 是脂肪细胞分化过程中的核心转录调控因子之一，参与调节脂肪细胞分化以及脂质摄取和储存相关基因的表达。前脂肪细胞实验发现，岩藻黄质及其在体内形成的代谢物岩藻黄醇，可能减少脂肪细胞分化过程中的脂质累积，并下调参与脂肪生成调控的 PPARγ[2]。这提示岩藻黄质的研究不仅涉及已储存脂质的利用，也涉及脂肪细胞形成和脂质储存的调控。

小结：第一条路径关注能量如何消耗，第二条路径关注脂肪细胞如何形成并储存脂质。

四、路径三：炎症与氧化应激

当城市的仓库长期爆满，交通和环境也会受到影响。脂肪组织过度扩张或肝细胞内脂质沉积增加时，细胞可能产生更多活性氧，并释放炎症相关信号，进而影响胰岛素信号、脂肪酸利用和肝脏脂质代谢。

这里的“慢性低度炎症”不同于急性感染引起的“红、肿、热、痛”，它程度较低、持续时间较长，可通过多种炎症介质影响胰岛素敏感性、脂肪酸利用和肝脏代谢，更像一种长期存在的“代谢烟雾”。脂质沉积、氧化应激和炎症信号之间可能相互促进：脂质沉积增加 → 氧化应激和炎症信号增强 → 代谢调节能力进一步下降 → 脂质更容易继续累积。

NF-κB 是参与炎症反应的重要转录调控因子，在炎症刺激下可促进多种炎症相关基因表达。现有细胞和动物研究提示，岩藻黄质可能影响 NF-κB 等炎症相关信号，并调节部分炎症和氧化应激指标[3,4]。这条路径关注的是脂质沉积、氧化应激、炎症信号与肝脏代谢之间的相互作用，而不是把炎症简单视为脂质增加的结果。

五、路径四：肝脏脂质代谢与调控

肝脏并不只是储存脂肪的器官，更像身体的脂质加工厂和调度中心：接收和处理脂肪酸，合成新的脂质，将脂质包装后输送到其他组织，并通过 β-氧化分解脂肪酸，是维持全身脂质稳态的重要器官。β-氧化可以简单理解为把较长的脂肪酸逐步拆解，转化为身体可继续利用的能量原料。

其中，PPARα 参与调节脂肪酸分解和氧化相关基因；CPT1A 是长链脂肪酸进入线粒体进行 β-氧化的重要调控环节，好比脂肪酸进入“燃烧车间”前的一道关口。

2024 年发表的一项研究结合细胞实验和小鼠模型发现，岩藻黄质能够减轻模型中的肝脏脂质沉积[5]。机制分析显示，岩藻黄质可能上调与脂肪酸 β-氧化相关的 PPARα 和 CPT1A，下调部分与脂质合成有关的转录因子和关键酶，并改善与线粒体形成和功能有关的信号。这些结果提示岩藻黄质可能参与肝脏脂质合成与脂肪酸氧化之间的平衡，使研究视角从单纯的“脂肪减少”延伸到脂肪组织与肝脏共同参与的代谢稳态。

小结：肝脏脂质状态不只取决于吃进来多少，而是脂肪酸输入、脂质合成、脂肪酸分解和脂质输出之间的动态平衡。

六、四条路径的关联逻辑

一个成分为什么既被体重管理研究关注，又被肝脏代谢研究关注？是同时有两种功效吗？

更准确的理解是：体重变化和肝脏脂质沉积，可能是同一个代谢网络中的两个观察窗口。二者都受能量摄入与消耗、脂肪细胞形成和储存能力、脂肪酸合成与氧化、线粒体相关代谢、炎症与氧化应激，以及肝脏对脂质代谢的调节能力等因素影响。因此，科研人员并不是简单地给岩藻黄质贴上“减脂”和“护肝”两个标签，研究关注的是：岩藻黄质是否能通过多个相互关联的代谢环节，影响能量利用、脂肪细胞形成、炎症环境和肝脏脂质处理。这种对整体代谢网络的理解，正是“代谢营养”与传统单一功效宣传的区别。

七、岩藻黄质的研究价值

岩藻黄质的研究价值并不来自某一个能解释全部作用的单一靶点，而在于它连接了多个代谢环节：一端是能量如何被消耗，一端是脂质如何被储存，中间还涉及脂肪细胞形成、线粒体功能、炎症信号和肝脏脂质代谢。从这个角度看，体重管理与肝脏健康并不是两个孤立的话题，而是人体能量与脂质代谢网络的不同侧面，这也是学界持续研究它的原因之一。需要强调的是，现有证据以细胞和动物研究为主，不能直接等同于人体食用效果。

延伸阅读：关于 BGG ThinOgen® 岩藻黄质的人体研究，请见本刊 S-04-05。

参考文献

1. Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun. 2005;332(2):392–397. doi:10.1016/j.bbrc.2005.05.002.

2. Maeda H, Hosokawa M, Sashima T, et al. Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int J Mol Med. 2006;18(1):147–152. doi:10.3892/ijmm.18.1.147.

3. Kim KN, Heo SJ, Yoon WJ, et al. Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol. 2010;649(1–3):369–375. doi:10.1016/j.ejphar.2010.09.032.

4. Tan CP, Hou YH. First evidence for the anti-inflammatory activity of fucoxanthin in high-fat-diet-induced obesity in mice and the antioxidant functions in PC12 cells. Inflammation. 2014;37(2):443–450. doi:10.1007/s10753-013-9757-1.

5. Zhang H, Tang Y, Zhang Y, et al. Fucoxanthin: a promising medicinal and nutritional ingredient. Evid Based Complement Alternat Med. 2015;2015:723515. doi:10.1155/2015/723515.

6. Bae M, Kim MB, Park YK, Lee JY. Health benefits of fucoxanthin in the prevention of chronic diseases. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(11):158618. doi:10.1016/j.bbalip.2020.158618.

7. Yang S, Li J, Yan L, et al. Molecular mechanisms of fucoxanthin in alleviating lipid deposition in metabolic associated fatty liver disease. J Agric Food Chem. 2024;72(18):10391–10405. doi:10.1021/acs.jafc.4c00590.

合规提示

本文用于科学研究、营养知识与原料信息交流，不构成对具体产品功效的承诺，也不构成疾病预防、诊断或治疗建议。本文提及的部分研究为细胞或动物研究，不能直接等同于人体食用效果。涉及产品的具体功效表述、适用范围和使用方式，应以目标市场法规及产品实际注册、备案或批准状态为准。

一、不只看体重数字，更关注“脂肪储存在哪里”

体重秤上的数字直观，却无法完整反映身体的真实变化：同等体重下降，来源可能是水分、肌肉或脂肪；脂肪分布位置不同，对应的健康风险也不同。

腹部脂肪分为皮下脂肪与内脏脂肪。皮下脂肪位于皮肤下方，可以用手捏到；内脏脂肪堆积在腹腔深处，包裹肝脏、肠道等器官。二者过量都会增加身体负担，而内脏脂肪的健康风险更值得重视：过度堆积时，脂肪组织会释放大量游离脂肪酸与炎症信号，干扰糖脂代谢，与胰岛素抵抗、血脂异常、高血压以及心血管风险升高相关。即便体重变化不大，内脏脂肪增多也提示代谢压力上升。

因此，体重管理不能只盯着体重下降多少。体重和 BMI 用于评估整体变化，腰围反映腹部脂肪累积趋势，CT 扫描则可以区分皮下脂肪和内脏脂肪，综合多项指标观察，比单看体重更有参考价值。

岩藻黄质是褐藻来源的天然类胡萝卜素，近年在代谢营养领域受到关注。细胞和动物实验显示，它可能参与能量消耗、脂肪细胞生成和脂质代谢调节；但体外与动物实验的结论能否适用于人体，需要靠原料自身的人体试验来检验。基于此，BGG 针对自有岩藻黄质原料开展了随机、安慰剂对照的人体试验。

二、BGG 岩藻黄质临床研究

研究对象与分组：共 19 名受试者，年龄 25～50 岁，BMI 23.0～40.0 kg/m²；受试者维持原有日常饮食，不额外节食、不增加运动，研究前 3 个月未服用其他体重管理类膳食补充剂。受试者随机分为 3 组：安慰剂组、岩藻黄质 2 mg/天组、岩藻黄质 4 mg/天组，每日早餐后 30 分钟服用 1 粒胶囊，连续 3 个月，每月检测体重。试验所用岩藻黄质提取自褐藻。

结果一：4 mg/天组从第 1 个月起体重出现持续变化

4 mg/天组基线平均体重为 78.6±9.0 kg，连续补充 3 个月后为 76.3±9.2 kg，较基线下降约 3%。与各组自身基线相比，4 mg/天组在第 1、2、3 个月均出现具有统计学显著性的体重下降，说明在本研究条件下，体重变化在第 1 个月即可见到，并持续到第 3 个月。

结果二：体重变化是否与“腹部脂肪”有关？

体重下降不等于脂肪减少。为确认体重变化是否来自腹部脂肪，研究人员选取前期体重下降较明显的 6 名受试者，从第 2 个月起在肚脐水平进行腹部 CT，测量内脏脂肪、皮下脂肪和总脂肪面积。第 2 个月至第 3 个月，这 6 名受试者的腹部总脂肪面积均下降：内脏脂肪平均面积下降 12.17 cm²，皮下脂肪平均面积下降 20.51 cm²，总脂肪面积下降 32.68 cm²。

腹部 CT 影像可以直观区分脂肪分布，比单纯体重读数提供更多信息。需要注意的是，该 CT 亚组仅 6 人，且为前期体重下降较明显者，结果宜谨慎解读。

结果三：3 个月使用期间的基础安全性观察

研究检测了红细胞、白细胞、血红蛋白等血液指标，以及尿糖、尿蛋白、尿胆红素、尿酮体等尿液指标。数据显示，连续服用 3 个月，各组肝酶、血细胞指标无显著异常，尿常规未发现异常。在本研究设置的 2 mg/天、4 mg/天剂量和 3 个月观察周期内，受试产品整体耐受性良好。

三、从褐藻活性成分到有研究依据的代谢营养方案

这项研究提示，体重管理的目标不应只是短期体重降低，还要看脂肪总量、脂肪分布，以及效果能否长期维持，不能把单次称重当作全部评判标准。岩藻黄质也不宜被简单定义为“快速减重成分”，本研究为代谢营养产品提供了一份人体研究数据作参考。

对长期健康管理而言，减少多余的腹部脂肪（尤其是内脏脂肪）价值不止在外观，也与长期代谢健康相关。据介绍，BGG 岩藻黄质的思路不是依靠抑制食欲、减少进食，而是依托海洋类胡萝卜素的分子结构参与能量与脂质代谢，在不改变原有生活方式的前提下开展观察。对于开发体重管理、代谢营养类产品的品牌方，这套基于原料人体试验、标准化生产、恪守科学边界的证据链，是 BGG 岩藻黄质的应用价值所在。

参考文献

Li Y, Iwata T, Sonoda K, Mi S. Fucoxanthin Supplementation Reduces Body Fat in Over Weight Humans: A Randomized, Placebo Controlled Study. Jpn Pharmacol Ther. 2015;43:1317-1322.

合规提示

本文内容不用于诊断、治疗、治愈或预防任何疾病。鉴于地域性法规差异，某些声明内容可能不适用于所有地区，相关产品的标签和声称需严格遵循当地政府的最新法律法规要求调整。上述仅供行业内部企业间的信息交流使用，不直接面对最终消费者，且不做出任何形式的保证。

——写给邢韶芳，和她还在丈量着的一年半

2025年2月18日，邢韶芳在海淀大恒大厦楼下被一道刷脸门拦住，一位路过的女士顺手替她刷了卡，还笑着寒暄两句——那正是公司的技术带头人李艳梅博士。面试开始没多久，她心里就已经认定：这是一家值得投入热爱的企业——国内较早深耕植物提取赛道，握着自己的拳头产品，老板又是技术专业出身，是行业里实打实的标杆。两个月后入职报到，同一扇门前，两人又一次遇见。李博士毫无架子，如老友般自然，这份如沐春风的平易近人，加上两次不期而遇的缘分，让邢韶芳对接下来的工作满怀期待。

一、从「提尽」到「够用」

入职后邢韶芳接手的第一个项目，是为一家海外客户开发一款原料的制备工艺。此前她的工作大多停留在实验室的基础研究里，追求把有效成分尽可能「提尽」，溶剂配比也习惯性放大——那是实验室思维里「精益求精」的样子。领导的一句提醒点醒了她：工艺不是做给试管看的，是要走进生产车间、走向市场的。

从那以后，她的天平上多了一个新的砝码：不只是「能不能提出来」，还要算清楚「值不值得提」。这是她口中这些年最大的变化——从一个单纯的实验室研究者，成长为懂得权衡工程现实的研发人。

二、规模变大，底色未改

在邢韶芳眼里，这一年多公司的成长是肉眼可见的：研发队伍一步步壮大，大家对核心产品的钻研愈发精益求精，脚步紧跟着国家中药现代化的方向往前走；合作模式也在悄悄迭代——从单纯交付研究成果，到如今与下游客户的研发部门深度绑定，并肩解决实际问题，不再是关起门做实验，而是走到产业前端，让技术真正对接市场需求。业务上，公司牢牢守住自身的核心优势，也敢于扎进市场尚属空白、有难度的新方向，凭这份敢闯敢试，去抢占先机。

让她感触最深的，是团队氛围始终没变：依旧团结友善，大家愿意碰撞想法、锐意进取。在她看来，规模扩张、业务向前探索，同时初心不变，是件很难得的事——团队壮大意味着肩上责任更重，短期难免遇到挑战，但这也是研发企业成长的必经之路。

三、教她如何回一条消息的人

接手一个合作项目时，她要独自对接对方研发部的同事，每周还要以PPT的形式同步进度。那段日子，她形容自己「满是焦虑」，生怕哪句话说得不妥，会拖累整个项目。

真正托住她的，是李艳梅博士和培楠总——不是高高在上的方向指点，而是具体到「这条消息该怎么回」的手把手带教。她说，正是这份毫无保留的言传身教，让她慢慢卸下包袱，学会从容地站在客户面前。

一年半的时间不算长，邢韶芳记住的也大多是些具体的小事：一次算错的溶剂配比，一场与下游客户深度绑定的项目磨合，一条反复斟酌措辞的消息。她说，正是这些具体的事，一点点教会了她怎么在这家公司里做研发。

写给自己，以及刚加入公司的新同事们

2025年4月，我们盛德邦的原生产经理调往云南公司，送军同志被公司委任了车间主任代生产经理一职。我记得那时候，他每天都要来我办公室多次。因为工作刚刚接手，一下子要面对一大堆生产管理事务，很多地方顾不过来。他让我帮他一起操心，我点头答应了。有时候我去他办公室，他正出神地对着电脑，我跟他说话，他也忘了回答。

随着职务的改变，挑战和压力一并到来。但好在他年轻、学习能力强，遇见问题也会迎难而上，即便过程中难免磕磕绊绊，也愿意沉下心来复盘调整。所以虽然并不完美，但在我们大家共同的努力下各项工作一步步理顺，整体得以稳步向前推进。

送军的老家是甘肃陇南的文县，聊天的时候，他给我们看他拍的家乡的视频：那可真是“一座座青山紧相连”。这个大山里的孩子说起家乡，人总是一脸的开心，而在我们工作了很多年的金可大家庭和盛德邦小家庭，我们彼此之间也像家人一样，互相帮助和扶持。

我们在生活和工作中，并不总是要准备好了才能开始，因为只要我们有足够的信念就必定能克服前行路上的困难。有句禅宗偈子说“竹密不妨流水过，山高岂碍白云飞”，岂不是对的呢。

我，在波尔塔瓦一个不起眼的小教堂里，当一名牧师。我们这距离市中心不算远，从赫尔洛伊夫大道转进来，只有两分钟的车程。赫尔洛伊夫，那是英雄的意思。

我这个牧师除了每星期带社区的信徒一起礼拜之外，主要工作就是听人忏悔、为人解惑。因为我爱圣经，爱上帝。上帝是那么的仁慈，那么的宽容，可世人对他的仁慈和宽容却那么的少。我期待自己回归天国，也热衷于为迷惑的人指引回归的道路。这是为什么，我选择这个收入低微，如今越来越受人排挤的职业。如果把时间拉长一点，我能感觉到前来寻求解惑的人，尤其是年轻人越来越少。他们似乎更喜欢去酒吧、去足球场，或去远足旅行，以这些方法排忧解难。记得三十年前，也就是苏联刚解体那会儿，来这里求助的人比现在要多得多，可能是饱受摧残、压抑太久的缘故吧。据我的导师科恩洛夫主教说，八十年前来的人更多，那是二战，即便在苏维埃政权的管控下，大家还是偷偷摸摸寻求神的指引。

人总是在瘟疫、战争，这种极度恐惧的时刻，才会想起神。

这不，新的战争已经开打两星期了，这是一个人的战争。哦，对了，现在是二零二二年的三月六号。过去几天，我这里每天都会有人，趁著空袭警报的间隙，前来哭诉，寻求精神抚慰。实际上，这个现象从年前就已经很明显了。遍布世界的瘟疫，像幽灵一样徘徊在地球的每个角落，伺机将苦难的阴影丢给相中的倒霉鬼。虽说过去两年乌克兰遭受的创伤有限，但从去年底开始，连续的两波疫情还是将人们的生活搅得七零八落。

就在上月，当所有人都认为战争还很远的时候，我曾为一个被瘟疫带走的倒霉鬼主持葬礼。他年过六十，家中妻子比他小三岁，膝下一双子女，已经成年了。玛莎，他的结发妻子告诉我：从被感染，到病情急剧恶化，不到三个月人就匆匆的走了。唯一的遗愿就是要在教堂举办葬礼。

前来参加悼念的家人、朋友泣不成声。或许不仅仅是失去至亲的缘故，也在于过去两年，疫情、经济给每个内心造成的重压。不过我呢，还是以相对的平和，将葬礼程序走完，然后温言开导受到最大打击的人。自然是他的爱人和孩子们。

“牧师先生，上帝为什么要夺走我的爱人？把我置于苦难之中？”玛莎止不住自己的眼泪。

我告诉她：“人死不是永别，而是回归；不是责罚，而是恩惠。您的丈夫离世之前很平静，证明他内心没有拒绝神的指引。所以迟早有一天，你们会再次相聚。”

我不是一个爱哭的人。

战争来得比所有人想象的快，甚至快于瘟疫，而且更加凶猛。俄军的导弹不由分说，将所有人从美梦中，拉回到冰冷、黑暗的现实中。前一天还在欢声笑语中度过的乌克兰，几小时后却成了炮火连天、血流成河的战场。听说基辅和哈尔科夫是普京大帝的核心目标，那里的情况更严重，但即便是我们这种暂时远离战争的市区，也因为阴沉的心而气温骤降。绚丽的阳光不再温暖，湛蓝的天空变成铅灰色，道路两旁原本散发著草木芬芳的森林，也被硝烟和炮火彻底污染了。这恐怕是乌克兰内心最寒冷的一个春天了。

我记得，就在战争刚刚开打那两天的一个傍晚，街道上已经空无一人。三五个年轻的小伙子突然推门进入教堂。他们身著笔挺的军服，神情时而紧张，时而愤怒，时而伤感。他们告诉我，自己是即将被派往战场，伏击俄军部队的一支反坦克小分队，最年轻的只有十七岁。

他嘴角抖动，向我哭诉道：“我叫科尔夫，服役还不到一年，本想锻炼一下自己的意志力，从没想到会面对真正的战争。我……我该怎么办？”

两个同伴看到他这副模样，原本阴沉的神情略微放松了一些，打趣道：“瞧你小子这熊样，一提起上阵杀敌就脸色惨白，没出息。唉！”接著他们自己也再次陷入到紧张的情绪中。

“我女儿只有两岁。我这一去，恐怕再也没机会逗她玩了。”其中一个叫博格丹的大男孩儿，说著眼圈儿就红了，但随即又闪烁出一丝坚毅的光芒，“不过能为家人而死，这辈子也值了！”

就这样我用心聆听他们的倾诉，从始至终没有多说什么，也不知道该说什么。只是平静地和他们讲述了上帝的宽容，并祝愿他们能够放弃恐惧，从死亡中找到自己生命的荣耀。一起祷告之后，士兵们就离去了。

我不是一个爱哭的人。

从这周一开始，战争的烈度似乎到了前所未有的水平。俄军的导弹开始轰炸城市的平民设施，看起来普京大帝口中的特别军事行动，是彻头彻尾的谎言。这是全面的侵略战争。不知道那几个士兵的命运如何，我没有再得到他们的讯息。只是无论我怎样祷告，每天都会有英勇的乌克兰士兵，从前线下来被送往医院，或者……火葬场。一场战争就这样无情的夺走了这么多年轻的生命，不仅有乌军，还有俄军。据说他们的伤亡更大，而在我眼里，只要放下武器，所有人都是上帝的孩子，没有人不是无辜的。

刚刚就在网上，我看到令人心碎的消息。在一个死去的俄军士兵身上，人们找到了屏幕粉碎的智能手机，依稀还可以看见上面的聊天记录。

“洛尔，你在哪里，为什么这么久不回信？你们真的还在训练营吗？”这是母亲给儿子的短信。

“不，妈妈，我们早就不在那里了。我不在训练营。”

“那你到底在哪里？爸爸想让我给你寄一个包裹。”

“你们还送什么包裹呀，妈妈！”

“什么，你在说什么？到底发生了什么？”

“妈妈，我在乌克兰呀。这里正在打仗，真的在打仗！我好害怕。我们在轰炸整座城市，甚至在射杀普通市民。他们说我们会在这里受到欢迎！但是我看到的，是太多的人用肉体挡在我们的卡车和坦克前面。他们骂我们纳粹恶魔呀，妈妈。这太难了。”

短信显示的时间，距离这个大男孩被炸死只有五分钟……

我不是一个爱哭的人。

瘫坐在屏幕前，我脑海中浮现出《辛德勒名单》中的旋律，一时悲从心来，一股难以抑制的窒息感从胸口传递到身体的每一根血管，随之而来的，是眼眶的灼热。我再也无法支配自己的情绪，泪如泉涌。

我之所以单单为这个俄罗斯男孩哭泣，因为他定是怀著巨大的惊恐和不安离世的。对于自己为何上战场，为何杀人，又为何要付出自己的生命，他一无所知。欺骗和背叛充斥著他们的心灵。

所有人从生下来，就在为死做准备。生命就是死亡的练习场。而死的道路不外乎两种，要么带著平静和荣耀回归上帝，那几乎是所有人的旅程，没什么好怕的；要么罕见的被恐惧和怨念裹挟，徘徊不前。这样的灵魂最终能否回归，还是灰飞烟灭，我心中没有底。不是上帝的宽容、仁慈不够，而是人心，我是说被恐惧浸透的人心，可能已看不见近在眼前的恩赐，他们会不由分说地将自己与上帝分隔开。